CLARITIN REDITABS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLARITIN REDITABS (CLARITIN REDITABS).
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
| Metabolism | Extensively metabolized in the liver via CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine; undergoes first-pass metabolism. |
| Excretion | Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total). |
| Half-life | Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment. |
| Protein binding | Loratadine: 97% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound. |
| Volume of Distribution | Loratadine: 4.5 L/kg. Desloratadine: 90 L/kg. High Vd indicates extensive tissue distribution. |
| Bioavailability | Orally disintegrating tablet: Bioequivalent to conventional tablets; absolute bioavailability ~100% (extensive first-pass metabolism: 3% parent drug reaches systemic circulation, but active metabolite contributes to effect). |
| Onset of Action | Orally disintegrating tablet: 1 hour. Antihistamine effect begins within 1–3 hours. |
| Duration of Action | 24 hours. Clinical note: Provides sustained symptom relief for allergic rhinitis and chronic idiopathic urticaria throughout the dosing interval. |
| Molecular Weight | 382.88 |
10 mg orally once daily.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | For GFR <10 mL/min: 10 mg orally every other day. No adjustment needed for GFR ≥10 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: 10 mg orally every other day. |
| Pediatric use | 6 years and older: 10 mg orally once daily. 2-5 years: 5 mg orally once daily (if using oral solution). REDITABS not recommended under 6 years. |
| Geriatric use | Adjust dosing based on renal function; more sensitive to anticholinergic effects; caution in patients over 65 with renal impairment. |
| 1st trimester | Limited human data; animal studies do not indicate direct or indirect harmful effects. Use only if clearly needed. |
| 2nd trimester | Limited human data; no known risk of fetal harm. Preferred antihistamine during pregnancy. |
| 3rd trimester | Limited human data; use near term may cause irritability or sedation in neonate. Use if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for CLARITIN REDITABS (CLARITIN REDITABS).
| Placental transfer | Loratadine crosses the placenta; fetal-to-maternal ratio not well defined. Based on molecular weight and lipophilicity, transfer is likely. |
| Breastfeeding | Small amounts excreted into breast milk; unlikely to cause adverse effects in infant. Weight of evidence suggests compatibility. Monitor infant for drowsiness. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to loratadine or any component of the formulation.Patients with severe hepatic impairment (Child-Pugh class C) due to lack of data.
| Precautions | Caution in hepatic impairment; dose adjustment recommended, Caution in severe renal impairment (CrCl <30 mL/min), May cause drowsiness; avoid driving if affected |
| Food/Dietary | No significant food interactions reported. Avoid concomitant use with alcohol as it may increase risk of drowsiness. Grapefruit juice does not significantly affect loratadine metabolism. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2: Safer |
| Teratogenic Risk | Loratadine (Claritin Reditabs) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. First trimester: In a large prospective study with 681 pregnant women exposed to loratadine, no increased risk of major congenital malformations was observed compared to unexposed controls. Second and third trimesters: Limited data, but no evidence of fetotoxicity or adverse neonatal outcomes. Overall, the risk is considered low, but use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required other than standard prenatal care. For chronic use during pregnancy, monitor maternal blood pressure and heart rate due to potential anticholinergic effects, though loratadine has minimal anticholinergic activity. In neonates, observe for irritability or sedation if maternal use near term. |
| Fertility Effects | No significant effects on fertility have been reported in animal studies or human data. Loratadine does not affect spermatogenesis or ovulation in reproductive toxicity studies. No known impact on conception rates. |
| Claritin Reditabs (loratadine) are orally disintegrating tablets that rapidly dissolve on the tongue, making them ideal for patients with swallowing difficulties. Onset of action occurs within 1-3 hours, with peak effect at 8-12 hours. Avoid use in severe hepatic impairment; consider dose adjustment for hepatic or renal impairment. |
| Patient Advice | Place the tablet on the tongue; it will dissolve rapidly without water. · Do not chew or swallow the tablet whole. · Use as directed for allergy symptoms; do not exceed 1 tablet per day. · May cause drowsiness in some patients; avoid driving until you know how you react. · Store in a dry place; do not remove from blister pack until ready to use. |